NASDAQ:CRVS Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free crvs Stock Alerts $1.61 +0.06 (+3.87%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$1.51▼$1.6550-Day Range$1.36▼$2.3652-Week Range$1.00▼$4.19Volume80,682 shsAverage Volume197,502 shsMarket Capitalization$78.95 millionP/E RatioN/ADividend YieldN/APrice Target$6.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Corvus Pharmaceuticals alerts: Email Address Corvus Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside311.5% Upside$6.63 Price TargetShort InterestHealthy3.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.47) to ($0.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.45 out of 5 starsMedical Sector710th out of 927 stocksPharmaceutical Preparations Industry316th out of 420 stocks 3.3 Analyst's Opinion Consensus RatingCorvus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCorvus Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.71% of the float of Corvus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorvus Pharmaceuticals has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Corvus Pharmaceuticals has recently decreased by 2.14%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCorvus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorvus Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRVS. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 2 news articles for Corvus Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 25 people have searched for CRVS on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows2 people have added Corvus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corvus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders31.30% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.64% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Corvus Pharmaceuticals are expected to decrease in the coming year, from ($0.47) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corvus Pharmaceuticals is -2.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corvus Pharmaceuticals is -2.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorvus Pharmaceuticals has a P/B Ratio of 2.04. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad MillPub😱 This phenomenon is smashing regular market gainsThanks to a little-known “Pathfinder” trading phenomenon… Traders have recently unlocked one of the most powerful idea-generation sources in the history of trading. At every single market open.Click here to save your seat and join the next LIVE workshop! About Corvus Pharmaceuticals Stock (NASDAQ:CRVS)Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.Read More CRVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRVS Stock News HeadlinesMay 1, 2024 | americanbankingnews.comCorvus Pharmaceuticals (NASDAQ:CRVS) Shares Pass Below 50-Day Moving Average of $1.83April 24, 2024 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (CRVS)May 1, 2024 | MillPub (Ad)😱 This phenomenon is smashing regular market gainsThanks to a little-known “Pathfinder” trading phenomenon… Traders have recently unlocked one of the most powerful idea-generation sources in the history of trading. At every single market open.April 17, 2024 | finance.yahoo.comHere's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 WeeksApril 9, 2024 | globenewswire.comCorvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisMarch 21, 2024 | seekingalpha.comCorvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | finanznachrichten.deCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMay 1, 2024 | MillPub (Ad)😱 This phenomenon is smashing regular market gainsThanks to a little-known “Pathfinder” trading phenomenon… Traders have recently unlocked one of the most powerful idea-generation sources in the history of trading. At every single market open.March 20, 2024 | finance.yahoo.comQ4 2023 Corvus Pharmaceuticals Inc Earnings CallMarch 19, 2024 | stockhouse.comCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 19, 2024 | globenewswire.comCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 16, 2024 | finance.yahoo.comCRVS Apr 2024 4.000 putMarch 13, 2024 | globenewswire.comCorvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024March 9, 2024 | finance.yahoo.comWe Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth CarefullyFebruary 17, 2024 | finance.yahoo.comCRVS Mar 2024 3.000 putFebruary 12, 2024 | msn.comCorvus Edges up on Disclosing DataFebruary 12, 2024 | finance.yahoo.comCorvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock UpFebruary 8, 2024 | marketwatch.comCorvus Pharmaceuticals Shares Rise on Orphan Drug DesignationFebruary 8, 2024 | msn.comCorvus lymphoma drug gets FDA orphan drug statusFebruary 8, 2024 | finance.yahoo.comCorvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell LymphomaFebruary 6, 2024 | finance.yahoo.comCorvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business OfficerJanuary 23, 2024 | finance.yahoo.comCorvus Pharmaceuticals Announces the Passing of Board Member Edith P. MitchellJanuary 5, 2024 | finance.yahoo.comIndividual investors in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) are its biggest bettors, and their bets paid off as stock gained 20% last weekDecember 13, 2023 | markets.businessinsider.comMaintaining Hold Rating on Corvus Pharmaceuticals Amid Steady but Unspectacular Clinical ProgressDecember 7, 2023 | msn.comAre Medical Stocks Lagging Corvus Pharmaceuticals (CRVS) This Year?November 21, 2023 | finance.yahoo.comIs Corvus Pharmaceuticals (CRVS) Stock Outpacing Its Medical Peers This Year?See More Headlines Receive CRVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today5/01/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CRVS CUSIPN/A CIK1626971 Webwww.corvuspharma.com Phone(650) 900-4520FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Target$6.63 High Stock Price Target$12.00 Low Stock Price Target$3.50 Potential Upside/Downside+327.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.63% Return on Assets-50.58% Debt Debt-to-Equity RatioN/A Current Ratio4.07 Quick Ratio4.07 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book1.96Miscellaneous Outstanding Shares49,040,000Free Float33,690,000Market Cap$76.06 million OptionableOptionable Beta1.02 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Richard A. Miller M.D. (Age 73)Co-Founder, President, CEO & Chairman of the Board Comp: $306kDr. Peter A. Thompson FACP (Age 64)M.D., Co-Founder & Independent Director Comp: $47kMr. Leiv Lea (Age 70)Chief Financial Officer Comp: $388.73kDr. William Benton Jones Ph.D. (Age 58)Senior Vice President of Pharmaceutical Development Comp: $346.42kDr. James T. Rosenbaum M.D.Senior Vice President of ResearchMr. Jeffrey S. ArcaraChief Business OfficerMore ExecutivesKey CompetitorsSpero TherapeuticsNASDAQ:SPROConnect BiopharmaNASDAQ:CNTBTempest TherapeuticsNASDAQ:TPSTAileron TherapeuticsNASDAQ:ALRNMarinus PharmaceuticalsNASDAQ:MRNSView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 6,200 shares on 2/2/2024Ownership: 0.000%Towerview LLCBought 94,395 shares on 2/1/2024Ownership: 0.891%Linda GraisBought 10,000 shares on 5/15/2023Total: $24,500.00 ($2.45/share)View All Insider TransactionsView All Institutional Transactions CRVS Stock Analysis - Frequently Asked Questions Should I buy or sell Corvus Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CRVS shares. View CRVS analyst ratings or view top-rated stocks. What is Corvus Pharmaceuticals' stock price target for 2024? 3 brokerages have issued twelve-month price targets for Corvus Pharmaceuticals' shares. Their CRVS share price targets range from $3.50 to $12.00. On average, they expect the company's share price to reach $6.63 in the next twelve months. This suggests a possible upside of 311.5% from the stock's current price. View analysts price targets for CRVS or view top-rated stocks among Wall Street analysts. How have CRVS shares performed in 2024? Corvus Pharmaceuticals' stock was trading at $1.76 at the beginning of 2024. Since then, CRVS stock has decreased by 8.5% and is now trading at $1.61. View the best growth stocks for 2024 here. Are investors shorting Corvus Pharmaceuticals? Corvus Pharmaceuticals saw a decrease in short interest in March. As of March 31st, there was short interest totaling 1,400,000 shares, a decrease of 6.0% from the March 15th total of 1,490,000 shares. Based on an average trading volume of 212,900 shares, the days-to-cover ratio is currently 6.6 days. Approximately 3.8% of the company's shares are short sold. View Corvus Pharmaceuticals' Short Interest. When is Corvus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our CRVS earnings forecast. How were Corvus Pharmaceuticals' earnings last quarter? Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released its earnings results on Tuesday, March, 19th. The company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14). What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO? 4 employees have rated Corvus Pharmaceuticals Chief Executive Officer Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among the company's employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 73.0% of employees surveyed would recommend working at Corvus Pharmaceuticals to a friend. What other stocks do shareholders of Corvus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO). When did Corvus Pharmaceuticals IPO? Corvus Pharmaceuticals (CRVS) raised $75 million in an initial public offering on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers. Who are Corvus Pharmaceuticals' major shareholders? Corvus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Ecor1 Capital, Llc, Leiv Lea, Linda Grais, Orbimed Advisors Llc, Richard A Md Miller and William Benton Jones. View institutional ownership trends. How do I buy shares of Corvus Pharmaceuticals? Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRVS) was last updated on 5/1/2024 by MarketBeat.com Staff From Our Partners😱 This phenomenon is smashing regular market gainsMillPubDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget Nvidia. This is the future of AIPorter & CompanyBiden out June 13; Kamala won’t replace him?Paradigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing4 coins to be the “Next Bitcoin”True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
